Damora Therapeutics, Inc. (DMRA)
NASDAQ: DMRA · Real-Time Price · USD
30.06
+2.06 (7.36%)
Sep 4, 2026, 4:00 PM EDT - Market closed

Damora Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-96.35-36.56-16.9-36.46-61.21-52.23
Net Income
-241.25-209.84-21.44-38.35-61.62-51.75
Earnings Per Share
-9.88-153.95-18.53-36.08-60.63-51.22
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
540.52257.6214.1833.1566.06109.24
Total Debt
-0.070.070.250.80.85
Net Cash (Debt)
540.52257.5614.132.965.25108.39
Net Cash Growth
5232.63%1726.38%-57.14%-49.58%-39.80%-33.37%
Net Cash Per Share
22.13188.9612.1930.9664.20107.27

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-44.52-6.73-18.62-36.91-42.93-52.31
Capital Expenditures
-----0.2-0.22
Free Cash Flow
-44.52-6.73-18.62-36.91-43.13-52.53
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.